{
  "docId": "019de077-2ede-72aa-ade1-9df6586a5c43",
  "docSlug": "07da8690ded5d079d6760889d2f598d8",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 31 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 31,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes two process diagrams illustrating the Benevolent Platform's role and the experimental validation process.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2ede-72aa-ade1-9df6586a5c43/14",
  "deckHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43",
  "deckJsonHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43.json",
  "deckAnchorHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.51,
        "y": 0.72
      },
      "kind": "diagram",
      "text": "Experimental validation process from biopsy to anti-inflammatory effect measurement",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18f83b8b-4948-4358-b085-f3401bcb0700",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "list",
      "text": "Significant commercial opportunity (IBD); UC predicted market size of $12.7bn by 2030; Crohn's disease predicted market size of $20.7bn by 2030; Robust recent IBD deal activity: $3.2bn, $250m, $212.5m",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12618583-e8d5-4622-80ac-a7b6af3c24e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "list",
      "text": "Rapid development, well validated, efficacious goal; Rapid and efficient preclinical candidate delivery - 2 years; Patient ex vivo biopsies; Comparable efficacy in Crohn's; Clinical - Positive Phase 1a results; Devoid of CNS side effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5545b81-9914-4544-a581-63dc3e11c68d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Novel (potential first-in-class); Programme goals in UC: Novel, Dual effect (barrier/inflammation), Oral small molecule; PDE10 - no prior linkage to UC in all available biomedical literature",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0ab5cb3-3edb-451c-88af-55ace8b64a8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1, 2. Evaluate Pharma, WW, 3. Company announcements",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e39ac403-b679-495b-b4f7-0888e15383bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "BEN-8744 – Ulcerative Colitis (UC) (PDE10 inhibitor) – on track for demonstrating clinical efficacy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8a3c858-2806-485c-8c7c-60d7805c6be0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "42ad03e4-a71e-4eeb-a159-8f842219ca5a",
      "evidence": "The list/bullet component describes the problem and goals for the BEN-8744 program, including the unmet need for an alternative oral small molecule treatment option.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}